The Gross Law Firm Notifies Shareholders of Revance Therapeutics, Inc.(RVNC) of a Class Action Lawsuit and an Upcoming Deadline

1. Revance Therapeutics faces class action for misleading statements about agreements. 2. Shareholders, buying during specified period, can join the lawsuit for recovery. 3. Claims involve distribution contract breaches affecting litigation risks and stock inflation. 4. The class period for claims spans from February 29, 2024, to December 6, 2024. 5. Lead plaintiff appointment deadline is set for March 4, 2025.

Legal

90

4m saved

Insight

Article

FAQ

Why Very Bearish?

The class action and allegations of misleading statements may negatively impact RVNC's stock price, similar to past cases like BioGen’s. Legal troubles often lead to loss of investor confidence and stock decline.

How important is it?

This article discusses a significant lawsuit directly involving RVNC, influencing investor sentiments and future stock performance. Legal challenges typically have heavier repercussions for stock prices.

Why Short Term?

Immediate concerns arise due to the upcoming lead plaintiff deadline, likely affecting RVNC's stock promptly. Similar situations have historically led to quick downturns in stock values.

Related Companies

RVNC TEOX BIIB

NOTICE TO SHAREHOLDERS OF REVANCE THERAPEUTICS, INC.

NEW YORK, Feb. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC).

Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/revance-therapeutics-inc-loss-submission-form-2/?id=127269&from=4

CLASS PERIOD:

February 29, 2024 to December 6, 2024

ALLEGATIONS:

The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Revance was in material breach of the Distribution Agreement with Teoxane, which granted Revance "the exclusive right to import, market, promote, sell and distribute Teoxane's line of dermal fillers; (ii) the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm; (iii) all the foregoing increased the risk that the tender offer would be delayed and/or amended; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

DEADLINE:

March 4, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/revance-therapeutics-inc-loss-submission-form-2/?id=127269&from=4

NEXT STEPS FOR SHAREHOLDERS:

Once you register as a shareholder who purchased shares of RVNC during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 4, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM?

The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

SOURCE The Gross Law Firm